CS 17919
Alternative Names: CS-17919Latest Information Update: 28 Sep 2024
At a glance
- Originator Chipscreen Biosciences
- Class Hepatoprotectants; Small molecules
- Mechanism of Action MAP kinase kinase kinase 5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Type 2 diabetes mellitus
- No development reported Non-alcoholic fatty liver disease
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Non-alcoholic-fatty-liver-disease in China
- 18 Jan 2022 Preclinical trials in Type 2 diabetes mellitus in China (unspecified route) (Chipscreen Biosciences pipeline, January 2022)
- 28 Aug 2020 Preclinical trials in Non-alcoholic fatty liver disease in China (unspecified route) before August 2020 (Biosciences pipeline, August 2020)